We hear the onion rings are great
So what else happened (didn't happen?) this weekend? A few stories below that IN VIVO Blog picked up on ...
- The New York Times writes on pharmaceutical and biotech companies' efforts to fight Alzheimer's disease. Wyeth and its "professorial" chief exec Robert Essner take center stage.
- Endo Pharmaceuticals presented positive data from a Phase III study of its Frova migraine therapy in menstrual migraine. The company has been hoping for years that a menstrual migraine indication would allow Frova to make some noise in the crowded triptan class. A supplemental NDA for the indication is on file with the FDA.
- And a few notes from this morning--IN VIVO Blog is on deadline for the monthly magazines so we mightn't get to these later on: Merck KGAA and Archemix expanded their aptamers alliance in a deal that sees Merck taking a $30mm stake in the biotech co. And good news for Schering-Plough; one of Organon's top prospects, the anesthesia drug sugammadex, posted solid data in a Phase III pivotal trial.
- So, David Chase's The Sopranos ended its eight year run last night, with a twisted reminder for viewers that not everything (not even every television show) achieves, deserves, or even needs resolution. Cop-out or genius?